Related Experiment Video
Updated: May 14, 2026
07:30
Transcanalicular Diode Laser-assisted Dacryocystorhinostomy for the Treatment of Primary Acquired Nasolacrimal Duct Obstruction
Published on: October 13, 2017
Sinus laser-assisted closure (SiLaC) in pilonidal sinus disease: a multicenter cohort study
J de Kort1, L V van Kempen2, R Schouten2
1Department of Surgery, Diakonessenhuis, P.O. Box 80250, 3508 TG, Utrecht, The Netherlands. jdkort1@diakhuis.nl.
Techniques in Coloproctology
|May 13, 2026
Summary
Sinus laser-assisted closure (SiLaC) offers a safe and effective minimally invasive treatment for sacrococcygeal pilonidal sinus disease (SPSD). Patients experience excellent symptom control and improved quality of life, with low rates of further surgical intervention.
Area of Science:
- Surgical Innovation
- Minimally Invasive Surgery
- Proctology
Background:
- Chronic sacrococcygeal pilonidal sinus disease (SPSD) management often involves surgical intervention.
- Sinus laser-assisted closure (SiLaC) is an emerging minimally invasive technique for SPSD.
- Limited long-term outcome data exist for SiLaC.
Purpose of the Study:
- To evaluate the mid-term outcomes of SiLaC for primary and recurrent SPSD.
- To assess symptom control, quality of life, and need for re-intervention after SiLaC.
- To contribute to the literature on the long-term efficacy of SiLaC.
Main Methods:
- Retrospective cohort study of 231 patients with primary or recurrent SPSD.
- Data collected from medical records and validated patient questionnaires.
- Follow-up assessed symptoms, quality of life (SF-36), and subsequent surgical needs.
Main Results:
- Median follow-up was 33 months.
- Additional surgery was needed in 27.3% (primary) and 29.1% (recurrent) SPSD.
- Treatment failure occurred in 18.0% (primary) and 20.4% (recurrent) SPSD, with low persistent symptoms and high quality of life.
Conclusions:
- SiLaC is a safe procedure for primary and recurrent SPSD.
- Excellent symptom control and high quality of life were observed post-SiLaC.
- Only 7.8% of patients required surgical treatment beyond SiLaC.
